Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126537974 | 12653797 | 4 | F | 20160914 | 20160816 | 20160928 | EXP | JP-ROCHE-1814007 | ROCHE | UEDA E, UEDA E, HASEBE H, TERASHIMA H, MATSUOKA N, SASAKI R, FUKUCHI T MACULAR HOLE AFTER ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.. FOLIA JAPONICA DE OPHTHALMOLOGICA CLINICA/THE 118TH NIIGATA OPHTHALMOLOGICAL MEE. 2016 2016;9(7):616-. | 51.00 | YR | M | Y | 0.00000 | 20160928 | OT | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126537974 | 12653797 | 1 | PS | LUCENTIS | RANIBIZUMAB | 1 | Other | 0.05 ML, UNK | U | U | 125156 | .05 | ML | SOLUTION FOR INJECTION | |||||
| 126537974 | 12653797 | 2 | SS | LUCENTIS | RANIBIZUMAB | 1 | Other | 0.05 ML, UNK | U | U | 125156 | .05 | ML | SOLUTION FOR INJECTION |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126537974 | 12653797 | 1 | Retinal vein occlusion |
| 126537974 | 12653797 | 2 | Macular oedema |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126537974 | 12653797 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126537974 | 12653797 | Macular hole | |
| 126537974 | 12653797 | Retinal vein occlusion |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |